Omada Health Inc

OMDA

Market cap $1.43B

SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its third quarter 2025 results on Thursday, November 6, 2025, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details A live audio webcast of the call will be available online at https://investors.omadahealth.com.

The approach defies the restrictive weight loss paradigm, with early results indicating increased meal tracking and member engagement1 with new real-time, personalized nutrition guidance SAN FRANCISCO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, launches Meal Map, a new nutrient-categorization tool that combines AI-powered instant feedback with human care teams to help members in its cardiometabolic programs understand the nutrient quality of their food choices. Built within Omada's Nutritional Intelligence capability, Meal Map is designed to help members make informed food choices, with an aim towards fostering confidence and long-term healthy habits.

Omada Health (OMDA) remains a buy, driven by accelerating membership growth, multi-condition adoption, and a massive underpenetrated market opportunity. OMDA's GLP-1 Care Track is a standout product, validated by clinical results and scaled distribution through major PBM partnerships, fueling enterprise customer wins. AI-driven efficiency gains are improving OMDA's operating leverage, supporting the path to gross margin expansion above 70% as the company scales.

Omada Health, Inc. (NASDAQ:OMDA ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 5:35 PM EDT Company Participants Sean Duffy - Co-Founder, CEO & Director Steven Cook - Chief Financial Officer Conference Call Participants Craig Hettenbach - Morgan Stanley, Research Division Presentation Craig Hettenbach VP & Equity Analyst Great. Well, good afternoon, everyone.

SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released results from a real-world analysis that showed 63% of Omada members maintained or continued to lose weight 12 months after discontinuing GLP-1s,1 challenging widespread assumptions of inevitable post-medication weight regain.

SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released new data¹ demonstrating that patients who used Omada's virtual physical therapy (PT) program to address musculoskeletal (MSK) conditions, Omada for Joint & Muscle Health, had lower utilization of total medical care and reduced MSK-related costs and encounters on average at 6 and 12 months compared to patients who used in-person PT (IP-PT). This study is believed to be one of the first peer-reviewed healthcare claims analyses to compare costs and utilization of virtual PT (V-PT) and IP-PT in treating MSK conditions while also accounting for the cost of the virtual program itself.

SAN FRANCISCO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference, taking place in New York, including a fireside chat on Tuesday, September 9, 2025, at 5:35 pm ET. The webcast will be available online at https://investors.omadahealth.com/news-events/events.

Omada Health reported quarterly results for the first time since its IPO in June. Omada's revenue increased 49% in its second quarter to $61 million.

Revenue of $ 61 million, up 49% 52% Member Growth and Significant Progress Toward Profitability SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) --  Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Highlights Total Members of 752,000, up 52% compared to the second quarter of 2024 Revenue of $61 million, up 49% compared to the second quarter of 2024 GLP-1 Companion Success, with strong growth in members being supported by Omada's GLP-1 companion programs - now available through two of the largest pharmacy benefit managers in the United States Omada Horizon Day: In May, Omada announced a new AI-agent, OmadaSpark, designed to deliver real-time motivational interviewing and nutrition education to members “I'm proud of our second quarter results, with 49% year-over-year revenue growth, strong margin improvements, and continued progress toward profitability,” said Sean Duffy, Co-founder and CEO of Omada Health.

I rate Omada Health a buy due to its strong clinical validation, strategic partnerships, and vast untapped market opportunity. OMDA's clinical outcomes, backed by 29 peer-reviewed studies, provide a true moat and credibility with sophisticated buyers like employers and health plans. Strategic partnerships with Cigna and CVS enable rapid scale, lower customer acquisition costs, and improve revenue visibility, accelerating OMDA's growth trajectory.